Meeting report. Acute promyelocytic leukemia-associated coagulopathy, 21 January 2004, London, United Kingdom.
Despite successful treatment with all-trans retinoic acid and chemotherapy, life-threatening bleeding remains a challenging complication of acute promyelocytic leukemia (APL). Indeed, bleeding and thrombosis are major complications of APL that lead to early death in approximately 10% of patients despite the success of current treatment. This condition may be attributed, in part, to the diffuse activation of coagulation, hyperfibrinolysis, and non-specific proteolytic activity that is observed in patients with APL. Therapeutic agents that induce the differentiation of leukemia cells improve outcomes compared with those observed using chemotherapy alone. They also correct the hyperactivity of the coagulation and fibrinolytic systems, thereby reducing early death from bleeding. Prophylactic therapy with newer anticoagulants may prove beneficial in patients with APL, but this must be confirmed in well-designed, randomized, controlled trials. A workshop was convened 21 January 2004 in London, England, to discuss the clinical and biological aspects of the APL-associated coagulopathy and the application of recent findings to the management of patients with APL. Eight speakers participated in the workshop. This meeting report provides synopses of their presentations and a summary of highlights from the meeting.
Tallman
Martin S
MS
Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Centre, 676 N. St. Clair Street, Suite 850, Chicago, IL 60611, USA. m-tallman@northwestern.edu
Brenner
Benjamin
B
Serna
Javier de la
Jde L
Dombret
Hervé
H
Falanga
Anna
A
Kwaan
Hau C
HC
Liebman
Howard
H
Raffoux
Emmanuel
E
Rickles
Frederick R
FR
D000925:Anticoagulants / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005342:Fibrinolysis / Q000502:physiology; D006470:Hemorrhage / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000150:complications / Q000188:drug therapy*; D013927:Thrombosis / Q000188:drug therapy / Q000209:etiology*; D014212:Tretinoin / Q000627:therapeutic use*
D000925:Anticoagulants; D000970:Antineoplastic Agents; D014212:Tretinoin